Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2018 | Can atezolizumab succeed where BCG fails in bladder cancer?

Peter Black • 8 Feb 2018
GU Cancers 2018
Bladder Cancer Genitourinary Cancer Atezolizumab BCG

BCG immunotherapy is one of the primary treatment options for bladder cancer patients who are ineligible for cystectomy. However, some patients continue to have persistent high-grade disease long after treatment, prompting the development of new drugs such as atezolizumab. In this video, Peter Black, MD, of the University of British Colombia, Vancouver, Canada, discusses a clinical trial investigating the efficacy of atezolizumab in BCG-unresponsive bladder cancer (NCT02844816). This interview took place at the 2018 Genitourinary Cancers Symposium in San Francisco, CA.

More from Peter Black

Immunotherapy approaches for NMIBC
6:08
Immunotherapy approaches for NMIBC
Peter Black • 19 Jul 2020
Genomic subtyping in bladder cancer
3:35
Genomic subtyping in bladder cancer
Peter Black • 19 Jul 2020
Using biomarkers to identify bladder cancer patients for neoadjuvant therapy
2:48
Using biomarkers to identify bladder cancer patients for neoadjuvant therapy
Peter Black • 8 Feb 2018
Systemic treatments for non-muscle invasive bladder cancer
1:08
Systemic treatments for non-muscle invasive bladder cancer
Peter Black • 8 Feb 2018

Related Videos

TROPHY-U-01: cohort 7 of SG, EV and zimberelimab in untreated mUC
2:25
TROPHY-U-01: cohort 7 of SG, EV and zimberelimab in untreated mUC
Randy Sweis • 23 Oct 2026
CCTG PR21: patient-reported QoL with docetaxel vs lutetium-PSMA in mCRPC
3:22
CCTG PR21: patient-reported QoL with docetaxel vs lutetium-PSMA in mCRPC
Daniel Khalaf • 23 Oct 2026
Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals